Published Books
Edited by Ranjita Shegokar
Drug Delivery Landscape in Cancer Research examines the combined impact of prevention, diagnosis and treatment of cancer. With a strong focus on the status, challenges, and prospects of cancer drug delivery technology, the book also examines the clinical translation-related knowledge and the development of different organ related cancers. In 22 chapters this book describes the current and new drug delivery systems in twenty different cancer, it gives insight drug delivery strategies and tumour microenvironment management in oral and ocular cancers. This book is a timely and valuable resource for health professionals, scientists and researchers, health practitioners, students, and all those who wish to broaden their knowledge in the allied field. “Drug Delivery Landscape in Cancer Research” is written by experts in the field and informed with facts directly from manufacturers. Pharmaceutical scientists, medical researchers, biomedical engineers and clinical professionals will find this an essential reference.
Edited by Ranjita Shegokar
Biomarker Landscape in Cancer Research examines the impact of early detection, predication of aggressiveness, and the determination of the best treatment for cancers. With a strong focus on the status, challenges, and prospects of biomarker measurements’ tools and technology, the book also examines clinical translation-related knowledge and the prognosis of different organ related cancers. In 21 chapters, it describes current and new diagnostic tools in twenty different cancers and explores how innovations in the cancer diagnostic space could make cancer screening and early detection more straightforward.
This book is a timely and valuable resource for health professionals, scientists and researchers, health practitioners, students, and all those who wish to broaden their knowledge in the allied field.
Edited by Ranjita Shegokar
Biomarker Landscape in Cancer Research examines the impact of early detection, predication of aggressiveness, and the determination of the best treatment for cancers. With a strong focus on the status, challenges, and prospects of biomarker measurements’ tools and technology, the book also examines clinical translation-related knowledge and the prognosis of different organ related cancers. In 21 chapters, it describes current and new diagnostic tools in twenty different cancers and explores how innovations in the cancer diagnostic space could make cancer screening and early detection more straightforward.
This book is a timely and valuable resource for health professionals, scientists and researchers, health practitioners, students, and all those who wish to broaden their knowledge in the allied field.
Edited by Ranjita Shegokar
Preclinical Cancer Landscape discusses the issues in preclinical-to-clinical translatability of molecularly targeted cancer therapies and the need to better align tumour biology in patients With a strong focus on the status, challenges, prospects and the need of robustness of preclinical cancer research, the book acknowledges that the bar for reproducibility in performing and presenting preclinical studies must be raised to facilitate a transparent discovery process that frequently and consistently leads to significant patient benefit. In 22 chapters this book describes the current status of preclinical research in multiple cancers. This book is a timely and valuable resource for health professionals, scientists and researchers, health practitioners, students, and all those who wish to broaden their knowledge in the allied field. ” Preclinical landscape in cancer research ” is written by experts in the field and informed with facts directly from manufacturers. Pharmaceutical scientists, medical researchers, biomedical engineers and clinical professionals will find this an essential reference.
Edited by Ranjita Shegokar
Cancer, a multifaceted disease, remains the leading cause of death worldwide. Ongoing research and technological advancements are continually improving the human understanding of newer treatment options. This book series aims to provide wide-ranging insights into the current landscape of cancer research, highlighting the recent advancements, current challenges, and future directions.
Cancer varies widely in its formation, microenvironment, location in the body, associated risk factors, detection methodology, and treatment approaches. Early detection and prevention through lifestyle changes, regular screenings, and the awareness of symptoms are crucial for improving outcomes and survival rates. In this book series, the main focus is on trending topics, like new drug delivery, diagnostics, biomarkers, and preclinical and clinical developments in cancer research. Nanotechnology has emerged as a transformative approach in medicine, particularly in the areas of targeted drug delivery systems, imaging, and diagnostics to enhance the therapeutic efficacy and minimize adverse effects in cancer therapy. Advances in pharma, medical device, and diagnostic research, including the development of Trojan-horse therapies and precision treatments/assay kits, continue to enhance the effectiveness of cancer care over the past few decades.
A total of five books are covered in this series:
- Drug Delivery Landscape in Cancer Research (Vol. 1)
- Biomarker Landscape in Cancer Research (Vol. 2)
- Diagnostic Landscape in Cancer Research (Vol. 3)
- Preclinical Landscape in Cancer Research (Vol. 4)
- Clinical Landscape in Cancer Research (Vol. 5)
By integrating basic, applied, and innovative science concepts, this book series fosters a deeper understanding of the disease and paves the way for the development of more effective strategies.
This book series serves as a valuable resource for students, researchers, regulators, and clinicians interested in understanding the complexities of cancer and the innovative approaches researched to combat this deadly disease. Nonetheless, continuous interdisciplinary, cross-country collaborations and cross-science innovation strategies are essential to further reduce the global cancer burden.
Edited by Ranjita Shegokar
The Peritoneal cavity (PC) is the key metastatic site for intra-abdominal malignancies (e.g., GI tract and rectal cancer). PC sites can be used to target several other diseases where lymphatic drug delivery is desired without dumping large amounts of the drug. Till recently, it was thought that treatment with curative intent was impossible but that was challenged by the introduction of cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC), and PIPAC (pressurized intraperitoneal aerosol chemotherapy). Recently, a growing number of preclinical and clinical studies advocate intraperitoneal (IP) chemotherapy as an alternative post-operative therapy for cancer. Although their effectiveness has been proven both experimentally and clinically, there is still little understanding of the role of drug delivery systems (DDS) in targeting drugs in the intraperitoneal (IP) cavity.
Exploring Drug Delivery to the Peritoneum Edited by Ranjita Shegokar Publisher –
Springer Cham, ISBN
978-3-031-31696-8(Softcover) / eBook ISBN
978-3-031-31694-4(Published: November 2023)
Edited by Ranjita Shegokar
Comprehensive yet succinct insight into the prevention, diagnosis, and treatment of infectious diseases including COVID-19, mpox, Ebola, and Lyme disease.
Rising Contagious Diseases provides basic information about preventing and treating threatening infectious diseases from viral, bacterial, and parasitic sources, including 28 emerging or recurring diseases like COVID-19, mpox, Ebola, bird and swine flu, malaria, Legionnaires’, and others. The text highlights molecular surveillance and epidemiology (including zoonotic pathogens or their variants), innovative strategies for pathogen detection, drug and vaccine development, appropriate preventive measures, cost-effective diagnostic procedures (assays), and effective therapeutic strategies.
Rising Contagious Diseases: Basics, Management, and Treatments Edited by Seth Kwabena Amponsah, Ranjita Shegokar, Yashwant V. Pathak, ISBN: 978-1-394-18873-4(January 2023)
Edited by Ranjita Shegokar
The disability-adjusted life year (DALY) is a generic measure of health effect that can be used in cost-effectiveness analysis as an alternative to the quality-adjusted life year (QALY). Infectious diseases are one of the major to cause significant losses of DALY and QALY. Human infectious diseases are disorders that are triggered by the micro-organisms such as bacteria, fungi, viruses, or parasites. The majority of such diseases are contagious and create a public health menace. There are several reasons why infectious diseases are deadly diseases, and one of the primary reasons is the drug resistance developed over time. Drug resistance-associated mutations are linked to increasing drug efflux, modifications of the drugs, or their targets. Every year, new drugs are being approved by FDA to treat infectious diseases. Nonetheless, the infectious diseases will undoubtedly persist as permanent and main threats to humanity for now and in the future.
Infectious Diseases Drug Delivery Systems Edited by Ranjita Shegokar, Yashwant Pathak Publisher –
Springer Cham, Hardcover ISBN
978-3-031-20520-0, Softcover ISBN
978-3-031-20523-1, eBook ISBN
978-3-031-20521-7(May 2023).
Edited by Ranjita Shegokar
The disability-adjusted life year (DALY) is a generic measure of health effect that can be used in cost-effectiveness analysis as an alternative to the quality-adjusted life year (QALY). Infectious diseases are one of the major to cause significant losses of DALY and QALY. Human infectious diseases are disorders that are triggered by the micro-organisms such as bacteria, fungi, viruses, or parasites. The majority of such diseases are contagious and create a public health menace. There are several reasons why infectious diseases are deadly diseases, and one of the primary reasons is the drug resistance developed over time. Drug resistance-associated mutations are linked to increasing drug efflux, modifications of the drugs, or their targets. Every year, new drugs are being approved by FDA to treat infectious diseases. Nonetheless, the infectious diseases will undoubtedly persist as permanent and main threats to humanity for now and in the future, primarily due to increased longevity that almost always comes at a cost of impaired immunity.
Viral Drug Delivery Systems Edited by Ranjita Shegokar, Yashwant Pathak Publisher –
Springer Cham, Hardcover ISBN
978-3-031-20536-1, Softcover ISBN
978-3-031-20539-2, eBook ISBN
978-3-031-20537-8(April 2023).
Edited by Ranjita Shegokar
The book targets new advances in areas of treatment and drug delivery sciences for tuberculosis. It covers advances in drug therapy and drug targeting that focus on innovative trend defining technologies and drug delivery platforms in the understanding of host-pathogens relationship for providing better therapy. A wide variety of novel and nano-formulations using promising technologies are being explored to deliver the drug via different administration routes. This book It addresses the gap between new approaches and old treatment modalities and how they are superior in pharmacological performance when tested in in-vitro and in-vivo. Audience from wide range group like from researchers to regulatory bodies can benefit from the compiled information to find out patient needs and current research advances in the field of tuberculosis research.
Tubercular Drug Delivery Systems Edited by Ranjita Shegokar, Yashwant Pathak Publisher –
Springer Cham, Hardcover ISBN
978-3-031-14099-0, Softcover ISBN
978-3-031-14102-7, eBook ISBN
978-3-031-14100-3(March 2023).
Edited by Ranjita Shegokar
This book targets new advances in areas of treatment and drug delivery sciences for Malaria. This is the only published book which compiles the complete road map of malarial drug delivery systems along with an overview on the pathology, current state of malaria across the globe, new clinical trials, emerging drugs and evolving novel drug delivery platforms. A wide variety of novel micro-and nano-formulations using promising technologies are being explored to deliver the malarial drug via different administration routes. This book addresses the gap between new approaches and old treatment modalities and how the former is superior in pharmacological performance when tested in in-vitro and in-vivo. Audience from wide range group like from researchers to regulatory bodies can benefit from the compiled information to find out patient needs and addresses a much-needed update to the existing malaria drug delivery research.
Malarial Drug Delivery Systems Edited by Ranjita Shegokar, Yashwant Pathak Publisher –
Springer Cham, Hardcover ISBN
978-3-031-15847-6, Softcover ISBN
978-3-031-16506-1, eBook ISBN
978-3-031-15848-3(March 2023).
Edited by Ranjita Shegokar
“Cell niches are present in several human body tissues as a dynamic microenvironment essential to modulate stem cells’ behavior in health, under injury, and in regenerative processes. The interplay between stem cells and their niche is necessary for sustaining tissues. The extracellular matrix (ECM) is the crucial component of the stem cell. It defines the architectural space, physical binding to the cell membrane, and interactions with the neighborhood cells and supports physical stress. Domains with nano or micrometric sizes define the surface and topology of the ECM, mediating cell interactions and macrophage recruitment to injured sites.
Nanotechnology and Regenerative Medicine
History, Techniques, Frontiers, and Applications Edited by Maria H. Santana, Eliana B. Souto, Ranjita Shegokar Language: English
Paperback ISBN: 9780323904711
9 7 8 – 0 – 3 2 3 – 9 0 4 7 1 – 1
eBook ISBN: 9780323904322 (November 2022)
Edited by Ranjita Shegokar
Characterization of Micro and Nanoparticles for Biomedical Applications is a helpful guide for industry researchers, academicians, regulatory experts and material scientists working in the field of pharmaceuticals, cosmeceuticals, nutraceuticals, agriculture, food, fragrance, and in the chemical industries. It aims to provide a one-stop resources on all the analytical techniques used in the field of micro and nanoparticles evaluation and characterization. The book’s chapters bring together knowledge on current analytical methodologies, limitations and advances in the in vitro analysis field. Users from the equipment industry will benefit from its innovations by understanding the needs of researchers and the challenges of current techniques. With the expectation of “high-quality data” essentially dependent on the analytical methodology applied for characterization, this is integral to success. For routine products like tablets, capsules, and solutions, the regulatory guidelines, product-specific monographs, and pharmacopoeial annexures are set and “standard of operation.” However, for nano-micro pharmaceuticals, regulatory guidelines are still evolving.
Edited by Ranjita Shegokar
Completely dedicated to the biomedical applications of metal nanoparticles, this book covers the different toxicity problems found in healthcare situations and also provides comprehensive info on the use of metal nanoparticles in treating various diseases. Metal Nanoparticles in Pharma is the first edited volume to set up the discussion for a clinical setting and to target a pharmaceutical audience of academic and industry-based researchers.
Metal Nanoparticles in Pharma, Mahendra Rai and Ranjita Shegokar (Editors) Springer publishing house, proposed publication, ISBN 978-3-319-63789-1 (Hard cover) / ebook
ISBN 978-3-319-63790-7 (May 2017 published).
Edited by Ranjita Shegokar
Emerging Nanotechnologies in Immunology aims to deliver a systematic and comprehensive review of data concerning the nature of interaction and nano-related risks between the nanophamaceuticals currently in the pipeline of S&T development for skin, ocular, and nasal drug delivery, including absorption, toxicity, and the ability to distribute after systemic exposure.
The scientific development of manufactured nanomaterials for drug delivery is increasing rapidly. One of the most prominent applications is topical drug delivery, where cutaneous, ocular, and nasal exposure becomes even more relevant. These targets are the first barrier that nanoparticles encounter when in contact with the human body. The contributors addresses a representative set of the broad spectrum of nanopharmaceuticals currently being used, including cationic lipid nanoparticles, polymeric PLGA, PLA nanoparticles, biomacromolecules-based nanoparticles, and other scaffolds tissue engineered skin substitutes. Regulation and risk is also covered, since the safety of these nanophamaceuticals still represents a barrier to their wide innovative use.
“Emerging Nanotechnologies in Immunology: The Design, Application and Toxicology of Nanopharmaceuticals and Nanovaccines” Edited by Shegokar R., and Souto E.B. Elsevier Int publishing house, ISBN (Hardcover). 9780323400169 / ebook – 9780323401135 (May 2018)
The scientific development of manufactured nanomaterials for drug delivery is increasing rapidly. One of the most prominent applications is topical drug delivery, where cutaneous, ocular, and nasal exposure becomes even more relevant. These targets are the first barrier that nanoparticles encounter when in contact with the human body. The contributors addresses a representative set of the broad spectrum of nanopharmaceuticals currently being used, including cationic lipid nanoparticles, polymeric PLGA, PLA nanoparticles, biomacromolecules-based nanoparticles, and other scaffolds tissue engineered skin substitutes. Regulation and risk is also covered, since the safety of these nanophamaceuticals still represents a barrier to their wide innovative use.
“Emerging Nanotechnologies in Immunology: The Design, Application and Toxicology of Nanopharmaceuticals and Nanovaccines” Edited by Shegokar R., and Souto E.B. Elsevier Int publishing house, ISBN (Hardcover). 9780323400169 / ebook – 9780323401135 (May 2018)
Edited by Ranjita Shegokar
Nanopharmaceuticals reviews advances in the drug delivery field via nanovehicles or nanocarriers that offer benefits like targeted therapy and serves as a single dose magic bullet for multiple drug delivery with improved drug efficiency at a lower dose, transportation of the drug across physiological barriers as well as reduced drug-related toxicity. The chapters are written by a diverse group of international researchers from industry and academia.
The series Expectations and Realities of Multifunctional Drug Delivery Systems examines the fabrication, optimization, biological aspects, regulatory and clinical success of wide range of drug delivery carriers. This series reviews multifunctionality and applications of drug delivery systems, industrial trends, regulatory challenges and in vivo success stories. Throughout the volumes discussions on diverse aspects of drug delivery carriers, such as clinical, engineering, and regulatory, facilitate insight sharing across expertise area and form a link for collaborations between industry-academic scientists and clinical researchers.
Multifunctional Drug Delivery systems: Expectations and Realities, Ranjita Shegokar (editor) Volume 1 – Nanopharmaceuticals, Elsevier Int (Q1/2020) ISBN 9780128177785.
The series Expectations and Realities of Multifunctional Drug Delivery Systems examines the fabrication, optimization, biological aspects, regulatory and clinical success of wide range of drug delivery carriers. This series reviews multifunctionality and applications of drug delivery systems, industrial trends, regulatory challenges and in vivo success stories. Throughout the volumes discussions on diverse aspects of drug delivery carriers, such as clinical, engineering, and regulatory, facilitate insight sharing across expertise area and form a link for collaborations between industry-academic scientists and clinical researchers.
Multifunctional Drug Delivery systems: Expectations and Realities, Ranjita Shegokar (editor) Volume 1 – Nanopharmaceuticals, Elsevier Int (Q1/2020) ISBN 9780128177785.
Edited by Ranjita Shegokar
Delivery of Drugs: Expectations and Realities of Multifunctional Drug Delivery Systems, Volume Two examines the formulation of micro-nanosized drug delivery systems and recaps opportunities for using physical methods to improve efficacy via mechano-, electroporation. The book highlights innovative delivery methods like PIPAC, including discussions on the regulatory aspects of complex injectables. Written by a diverse range of international researchers from industry and academia, the chapters examine specific aspects of characterization and manufacturing for pharmaceutical applications as well as regulatory and policy aspects.
This book connects formulation scientists, regulatory experts, engineers, clinical experts and regulatory stakeholders. This level of discussion makes it a valuable reference resource for researchers in both academia and the pharmaceutical industry who want to learn more about the status of drug delivery systems.
Multifunctional Drug Delivery:Expectations and Realities, Ranjita Shegokar (editor), Volume 2 – Delivery of Drugs, Elsevier Int (Q1/2020) ISBN 9780128177761.
This book connects formulation scientists, regulatory experts, engineers, clinical experts and regulatory stakeholders. This level of discussion makes it a valuable reference resource for researchers in both academia and the pharmaceutical industry who want to learn more about the status of drug delivery systems.
Multifunctional Drug Delivery:Expectations and Realities, Ranjita Shegokar (editor), Volume 2 – Delivery of Drugs, Elsevier Int (Q1/2020) ISBN 9780128177761.
Edited by Ranjita Shegokar
Drug Delivery Trends examines a drift in the pharmaceutical field across the wide range of dosage forms, drug delivery systems (micro and nanoparticulate), at the regulatory front and on new types of therapies in the market. This volume additionally covers the challenges on drug delivery systems in terms of preclinical and current ways of determining quality and the options to solve the challenges associated with this. Most small-medium scale industries and academics struggle with initial regulatory challenges so a detailed discussion on regulatory trend covers the necessary basic understanding of regulatory procedures and provides the required guidance.
The series Expectations and Realities of Multifunctional Drug Delivery Systems examines the fabrication, optimization, biological aspects, regulatory and clinical success of wide range of drug delivery carriers. This series reviews multifunctionality and applications of drug delivery systems, industrial trends, regulatory challenges and in vivo success stories. Throughout the volumes discussions on diverse aspects of drug delivery carriers, such as clinical, engineering, and regulatory, facilitate insight sharing across expertise area and form a link for collaborations between industry-academic scientists and clinical researchers.
Multifunctional Drug Delivery: Expectations and Realities, Ranjita Shegokar (editor), Volume 3 – Drug Delivery Trends, Elsevier Int (Q1/2020) ISBN 9780128178706.
The series Expectations and Realities of Multifunctional Drug Delivery Systems examines the fabrication, optimization, biological aspects, regulatory and clinical success of wide range of drug delivery carriers. This series reviews multifunctionality and applications of drug delivery systems, industrial trends, regulatory challenges and in vivo success stories. Throughout the volumes discussions on diverse aspects of drug delivery carriers, such as clinical, engineering, and regulatory, facilitate insight sharing across expertise area and form a link for collaborations between industry-academic scientists and clinical researchers.
Multifunctional Drug Delivery: Expectations and Realities, Ranjita Shegokar (editor), Volume 3 – Drug Delivery Trends, Elsevier Int (Q1/2020) ISBN 9780128178706.
Edited by Ranjita Shegokar
Drug Delivery Aspects reviews additional features of drug delivery systems, along with the standard formulation development, like preclinical testing, conversion into solid dosage forms, roles of excipients and polymers used on stability and sterile processing. There is a focus on formulation engineering and related large scale (GMP) manufacturing, regulatory, and functional aspects of drug delivery systems. A detailed discussion on biologics and vaccines gives insights to readers on new developments in this direction.
The series Expectations and Realities of Multifunctional Drug Delivery Systems examines the fabrication, optimization, biological aspects, regulatory and clinical success of wide range of drug delivery carriers. This series reviews multifunctionality and applications of drug delivery systems, industrial trends, regulatory challenges and in vivo success stories. Throughout the volumes discussions on diverse aspects of drug delivery carriers, such as clinical, engineering, and regulatory, facilitate insight sharing across expertise area and form a link for collaborations between industry-academic scientists and clinical researchers.
Multifunctional Drug Delivery: Expectations and Realities, Ranjita Shegokar (editor), Volume 4 – Drug Delivery Aspects, Elsevier Int (Q1/2020) ISBN 9780128212226.
The series Expectations and Realities of Multifunctional Drug Delivery Systems examines the fabrication, optimization, biological aspects, regulatory and clinical success of wide range of drug delivery carriers. This series reviews multifunctionality and applications of drug delivery systems, industrial trends, regulatory challenges and in vivo success stories. Throughout the volumes discussions on diverse aspects of drug delivery carriers, such as clinical, engineering, and regulatory, facilitate insight sharing across expertise area and form a link for collaborations between industry-academic scientists and clinical researchers.
Multifunctional Drug Delivery: Expectations and Realities, Ranjita Shegokar (editor), Volume 4 – Drug Delivery Aspects, Elsevier Int (Q1/2020) ISBN 9780128212226.
